4
Changes in Ownership
Janux Therapeutics, Inc. Filed Acc 0001415889-24-024074
President and CEO sold 25,000 shares at an average $46.31 ($1,157,641)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Campbell David Alan President and CEO | 2024-09-27 | Sale 10b5-1 | −18,957 | $46.09 | $873,715 | 313,097 | D |
| Campbell David Alan President and CEO | 2024-09-27 | Sale 10b5-1 | −5,248 | $46.86 | $245,895 | 307,849 | D |
| Campbell David Alan President and CEO | 2024-09-27 | Sale 10b5-1 | −795 | $47.84 | $38,032 | 307,054 | D |
| Open-market sales · 25,000 sh · avg $46.31 · $1,157,641 | |||||||
Loading xslF345X05/form4-09272024_110948.xml…